AURORA (2009) — Trial Summary
AURORA (2009): Randomized, double-blind, placebo-controlled trial of rosuvastatin 10 mg once daily versus placebo in adults 50–80 years of age undergoing maintenance hemodialysis (NCT00240331). Primary composite: cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.
References
- Fellström BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis. N Engl J Med. 2009;360(14):1395-1407.